Viking Therapeutics Stock Surges on VK2735 Trial Success

Viking Therapeutics stock closed at $34.34, up 11.44%, fueled by VK2735 Phase 2 success. The trial delivered 14.7% average weight reduction, challenging GLP-1 leaders like Ozempic. Acquisition speculation boosts investor interest.

Shares of Viking Therapeutics, a clinical-stage biotechnology firm, rallied significantly, closing at $34.34 with an 11.44% gain. Investors showed renewed enthusiasm from strong clinical trial data and acquisition rumors by big pharma.

VK2735 Phase 2 VENTURE Trial Results

The key driver was positive data from VK2735, Viking's obesity drug candidate. In the Phase 2 VENTURE study, participants achieved an average 14.7% weight reduction.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store

Get it onGoogle Play

This positions VK2735 as a strong rival in the obesity treatment market, dominated by GLP-1 therapies like Ozempic and Wegovy.

Source Information

Originally published by Ad Hoc News.Read the original article →

Keep exploring

More in Medical Research

Health & Wellness

Wegovy, Zepbound & More: Hers Makes GLP-1s Accessible from $39

The journey to weight loss can be challenging, and for many, advanced medications like GLP-1 injectables offer a crucial pathway. However, their high cost often presents a significant barrier. Hers is changing this landscape by making popular GLP-1 and other weight loss treatments more accessible and affordable than ever before.

7 min read

Medical News

Retatrutide Phase 3 Results: 28% Weight Loss and the Triple Agonist Promise

Eli Lilly has released pivotal Phase 3 trial data for retatrutide, a triple agonist showing up to 28% body weight reduction and significant improvements in diabetes and sleep apnea.

7 min read

Medical Insights

Beyond GLP-1s: Unlocking Better Diabetes Control with Korlym

For individuals struggling with difficult-to-control type 2 diabetes and weight management, even powerful GLP-1 medications might not be enough. New research highlights the significant role of hypercortisolism and the promising potential of Korlym in optimizing treatment outcomes.

6 min read

VK2735 Phase 2 VENTURE Trial Results

The key driver was positive data from VK2735, Viking's obesity drug candidate. In the Phase 2 VENTURE study, participants achieved an average 14.7% weight reduction.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store

Get it onGoogle Play

This positions VK2735 as a strong rival in the obesity treatment market, dominated by GLP-1 therapies like Ozempic and Wegovy.

Source Information

Originally published by Ad Hoc News.Read the original article →

Keep exploring

More in Medical Research

Health & Wellness

Wegovy, Zepbound & More: Hers Makes GLP-1s Accessible from $39

7 min read

Medical News

Retatrutide Phase 3 Results: 28% Weight Loss and the Triple Agonist Promise

Eli Lilly has released pivotal Phase 3 trial data for retatrutide, a triple agonist showing up to 28% body weight reduction and significant improvements in diabetes and sleep apnea.

7 min read

Medical Insights

Beyond GLP-1s: Unlocking Better Diabetes Control with Korlym

6 min read